KALA

Kala Pharmaceuticals, Inc. Common Stock
NasdaqCMUSDEQUITY Healthcare DELAYED
Last price
0.84
▼ 0.00 (0.38%)
MARKET ·

Price

Open
0.89
Prev close
0.84
Day high
0.98
Day low
0.80
Volume
100.32K
Market cap
$15.86M
P/E (TTM)
52W range
0.59 – 1,030.00

Trailing performance

Price return · vs SPY
Returnvs SPY
1W
-13.32% -12.0%
1M
+34.43% +30.7%
3M
-68.46% -71.6%
6M
-95.68% -106.7%
YTD
-97.05% -109.3%
1Y
-99.80% -119.8%
3Y
-99.88% -174.1%
5Y

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported
Market cap$15.86M
Enterprise value$7.97M
Revenue (TTM)
Gross profit
EBITDA$-33.23M
Net income$-19.65M
EPS (TTM)$-9.39
Free cash flow$-20.64M
Total cash$8.76M
Total debt$0
Book value / share$12.56
Shares outstanding19.34M
Float18.59M
Short % of float1.45%
Dividend yield
Beta (5Y)-2.28

Valuation & profitability ratios

Account required
Trailing P/E
Forward P/E-0.12
PEG ratio
Price / sales
Price / book0.07
EV / revenue
EV / EBITDA-0.24
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-238.68%
Return on assets-69.27%
Debt / equity
Current ratio7.91
Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Financial statements

Annual · as reported
Last 4 fiscal years
Line item2024202320222021
Total revenue$0$0$3.89M$11.24M
Cost of revenue$0$0$0$0
Gross profit$0$0$0$0
R&D
SG&A
Operating income
Pre-tax income
Tax provision$0$0$0$0
Net income-$38.51M-$42.20M-$44.82M-$142.60M
EBIT$0$0$0$0

Earnings

History & consensus estimates
Reported vs expected · EPS
QuarterEst.ActualSurprise
Sep 2025 -50.50-53.50 -5.9%
Jun 2025 -102.00-65.94 +35.4%
Mar 2025 -127.00-50.66 +60.1%
Dec 2024 -123.50-61.58 +50.1%
Forward consensus
PeriodEPSAnalystsRevenueGrowth
Current quarter $0
Next quarter $0
Current year $0
Next year $0

Analyst targets & ownership

Account required
Mean target
High target
Low target
Implied upside
Analyst count
ConsensusNONE
Strong buy / Buy— / —
Hold
Sell / Strong sell— / —
Held by insiders1.24%
Held by institutions3.61%
Institutions holding23
Free account required

Price targets, consensus spread, insider and institutional ownership.

Insider net activity

6m · Form 4 rollup
Net shares
+22.65M
Net buying
Buy transactions
75
27.78M shares
Sell transactions
65
5.13M shares
Net transactions
+140
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
230.70K
Total on file
Bought 27.78MSold 5.13M

Insider transactions

Account required
DateInsiderAction SharesValueHeld
Oct 23, 25
IWICKI MARK T.
Director
SELL 154.89K $125.46K Direct
Oct 23, 25
REUMUTH MARY
Chief Financial Officer
SELL 33.20K $27.54K Direct
Oct 22, 25
BRAZZELL ROMULUS KIM
Officer
SELL 46.75K $38.80K Direct
Oct 22, 25
BAZEMORE TODD M
Director
SELL 47.77K $39.65K Direct
Oct 22, 25
KHARABI DARIUS
Officer
SELL 20.81K $17.27K Direct
Oct 1, 25
BAKER BROS ADVISORS, L.P.
Former
SELL 730.41K $1.06M Indirect
Jun 24, 25
IWICKI MARK T.
Director
SELL 13.23K $53.04K Direct
Jun 24, 25
BAZEMORE TODD M
Chief Executive Officer
SELL 4.06K $16.27K Direct
Jun 24, 25
REUMUTH MARY
Chief Financial Officer
SELL 3.63K $14.56K Direct
Jun 24, 25
KHARABI DARIUS
Officer
SELL 4.51K $18.09K Direct
Jun 13, 25
MYERS CHARLES DANIEL
Director
2.45K Direct
Jun 13, 25
FARID MARJAN
Director
2.45K Direct
Jun 13, 25
PERRY GREGORY D
Director
2.45K Direct
Jun 13, 25
KOVEN ANDREW IAN
Director
3.05K Direct
What this is, and what it is not

These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.

A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.

This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.

Free account required

Officer and director trades in their own stock, straight from Form 4 filings.

Insider holders

10 reporting
NameRelationShares heldLatest
BAKER BROS ADVISORS, L.P.
Former Sale
BAZEMORE TODD M
Director 35.93K Sale
BRAZZELL ROMULUS KIM
Officer 35.95K Sale
IWICKI MARK T.
Director 103.54K Sale
KHARABI DARIUS
Officer 41.76K Sale
KOVEN ANDREW IAN
Director 16.97K Stock Award(Grant)
MYERS CHARLES DANIEL
Director 10.37K Stock Award(Grant)
PERRY GREGORY D
Director 13.34K Stock Award(Grant)
REUMUTH MARY
Chief Financial Officer 28.91K Sale
ROSEN HOWARD B
Director 16.50K Stock Award(Grant)

Moving averages & technicals

Computed from 2Y daily closes
SMA 10
0.87
-4.05% from price
SMA 20
0.80
+2.98% from price
SMA 50
1.41
-41.77% from price
SMA 100
3.44
-75.67% from price
SMA 200
15.39
-94.67% from price
EMA 12
0.85
-1.84% from price
EMA 26
0.97
-13.74% from price
EMA 50
1.81
-53.68% from price
RSI (14)
37.9
Neutral
MACD (12,26,9)
-0.12
Hist 0.06
ATR (14)
0.10
11.72% of price
Realised vol 30D
113.1%
Annualised
Bollinger upper
0.98
20, 2σ
Bollinger lower
0.62
20, 2σ
50 / 200 cross
Death
1.41 vs 15.39
Trend bias
Below 200
-94.67%

Risk profile

Daily returns · 1Y window
Beta vs SPY
2.08
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
113.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-99.9%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.10
11.72% of price
Beta (reported)
-2.28
5Y monthly, from filing

Unusual options activity

Account required
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
Free account required

Contracts trading at or above their open interest, ranked by notional and where the print landed.

Options analytics

Account required
Put / call volume
Put / call open interest
Positioning, not flow
Max pain
ATM implied vol
Nearest strike to spot
Skew (10% OTM)
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
Heaviest put OI

Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.

Free account required

Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.

Options chain

Account required
ExpirySpot 0.84
Calls
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Puts
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Headlines

KALA · links out to the publisher

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.